Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14273521 | 0.88 | CASR (0.41) | CA1CA2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13768015 | 0.82 | CA1 (0.37) | CA1CA2ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL13513688 | 0.82 | CA1 (0.35) | CA1CA2CA7CA14ALDH1A1 | |
| SCHEMBL13767997 | 0.79 | CD40 (0.39) | — | |
| SCHEMBL13844133 | 0.79 | ALDH1A1 (0.36) | CA1CA2ALDH1A1LMNATP53 | |
| SCHEMBL13768301 | 0.73 | KDM4E (0.36) | CA1CA2ALDH1A1POLB | |
| SCHEMBL13844226 | 0.72 | KMT2A (0.33) | ALDH1A1LMNAMAPT | |
| SCHEMBL13767938 | 0.71 | ALDH1A1 (0.35) | CA1CA2ALDH1A1 | |
| SCHEMBL13764190 | 0.70 | SCN3A (0.44) | CA1CA2CA7CA14ALDH1A1 | |
| SCHEMBL13844187 | 0.70 | HDAC3 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1774410-B1 | CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | CANON KK (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20080064828-A1 | Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor | CANON KABUSHIKI KAISHA (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064828-A1 | Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor | FAR1, ACSL4, ACAD11 | CA1 1473/4885CA2 1054/4885CA7 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.